Esperion Therapeutics (NASDAQ:ESPR) reported Q2 EPS of ($1.05), $0.12 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $0 versus the consensus...
Esperion Therapeutics (NASDAQ:ESPR) reported Q1 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $18.8 million versus the...
Investors in Esperion (NASDAQ:ESPR) Therapeutics, Inc. ESPR need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 21, 2022...
Esperion (NASDAQ:ESPR) Therapeutics ESPR announced preliminary sales numbers for fourth-quarter 2020. Notably, the company’s expectation for the quarter looks gloomy....
Stocks fought back from another lower open on Friday, but it wasn’t enough to save the whole week as the plunges on Tuesday and Wednesday proved too severe to...
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
|Average||10.80 (+61.19% Upside)|
|No. of Analysts||10|